Maj-britt R. Jensen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 127 publications

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026

Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial.

Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial.

Journal: Clinical and translational radiation oncology
Published: February 03, 2026

Development and Validation of an Algorithm to Achieve Complete Registration of Danish Patients with Carcinoma In Situ of the Breast, 2008-2023.

Development and Validation of an Algorithm to Achieve Complete Registration of Danish Patients with Carcinoma In Situ of the Breast, 2008-2023.

Journal: Clinical epidemiology
Published: November 06, 2025

AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.

AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.

Journal: NPJ breast cancer
Published: October 24, 2025

Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.

Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.

Journal: Danish medical journal
Published: October 10, 2025

ASO Author Reflections: Is Axillary Lymph Node Dissection Always Justified for Residual Axillary Disease in Breast Cancer After Neoadjuvant Chemotherapy?

ASO Author Reflections: Is Axillary Lymph Node Dissection Always Justified for Residual Axillary Disease in Breast Cancer After Neoadjuvant Chemotherapy?

Journal: Annals of surgical oncology
Published: August 21, 2025

Statin use and risk of contralateral breast cancer: an updated cohort study with landmark analysis.

Statin use and risk of contralateral breast cancer: an updated cohort study with landmark analysis.

Journal: European journal of epidemiology
Published: August 11, 2025

Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients.

Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients.

Journal: Breast (Edinburgh, Scotland)
Published: July 22, 2025

Oncologic First Events in Breast Cancer Patients After Targeted Axillary Dissection.

Oncologic First Events in Breast Cancer Patients After Targeted Axillary Dissection.

Journal: Annals of surgical oncology
Published: June 11, 2025

Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study.

Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study.

Journal: Acta oncologica (Stockholm, Sweden)
Published: May 29, 2025

Enhancing HER2-low breast cancer detection with quantitative transcriptomics.

Enhancing HER2-low breast cancer detection with quantitative transcriptomics.

Journal: NPJ breast cancer
Published: May 20, 2025

Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.

Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.

Journal: Breast cancer research and treatment
Published: February 13, 2025
Showing 1-12 of 127

Last Updated: 09/26/2026